Cited by 1,860HER2/EGFR in Cancer ResearchGastric Cancer Management and OutcomesLung Cancer Treatments and Mutations

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Vogel, Charles L., Cobleigh, Melody A., Tripathy, Debu, Gutheil, John C., Harris, Lyndsay N., Fehrenbacher, Louis, Slamon, Dennis J., Murphy, Maureen, Novotny, William F., Burchmore, Michael, Shak, Steven, Stewart, Stanford J., Press, Michael·2002·Journal of Clinical Oncology

DOI 10.1200/jco.2002.20.3.719

Open this paper in CoChat — free account

Abstract

PURPOSE: To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS: One hundred fourteen women with HER2-overexpressing metastatic breast cancer were randomized to receive first-line treatment with trastuzumab 4 mg/kg loading dose, followed by 2 mg/kg weekly, or a higher 8 mg/kg loading dose, followed by 4 mg/kg weekly. RESULTS: The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses. Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively. The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively. The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively. Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later. The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%). Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab. There was no clear evidence of a dose-response relationship for response, survival, or adverse events. CONCLUSION: Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.

Integrity signals

Registry

Crossref · 10.1200/jco.2002.20.3.719

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Self-citation
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citation
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Self-citation
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
Self-citation
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P. M., Presta, L. G., Gorman, C., Ridgway, J. B., Henner, D. J., Wong, W., Rowland, A. M., Kotts, C. E., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,926
The biology of erbB-2/nue/HER-2 and its role in cancer
Hynes, N. E. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90012-4 · Cited by 974
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review
Ravdin, P. M., & Chamness, G. C. (1995) · Gene · doi:10.1016/0378-1119(94)00866-q · Cited by 250
c-erbB-2 oncoprotein expression in primary and advanced breast cancer
Lovekin, C., Ellis, I. O., Locker, A. P., Robertson, J., Bell, J., Nicholson, R., Gullick, W., Elston, C., & Blamey, R. W. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.101 · Cited by 237

Flagged first, then by citations

Show all 9 references

Sorted by citations

Items 901–1,000 of 1,009

High‐expression EGFR/cell membrane chromatography‐online‐high‐performance liquid chromatography/mass spectrometry: rapid screening of EGFR antagonists from Semen Strychni
Sun, M., Guo, Y., Dai, B., Wang, C., & He, L. (2012) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.6318 · Cited by 28
Identification of Predictive Biomarkers for Response to Trastuzumab Using Plasma FUCA Activity and N-Glycan Identified by MALDI-TOF-MS
MATSUMOTO, K. Y., Shimizu, C., Arao, T., Andoh, M., Katsumata, N., Kohno, T., Yonemori, K., Koizumi, F., Yokote, H., Aogi, K., et al. (2009) · Journal of Proteome Research · doi:10.1021/pr800655p · Cited by 28
The ErbB Receptors as Targets for Breast Cancer Therapy
Albanell, J., & Baselga, J. M. (1999) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1018762216147 · Cited by 28
Use of a Population Pharmacokinetic Approach for the Clinical Development of a Fixed‐Dose Subcutaneous Formulation of Trastuzumab
Hourcade‐Potelleret, F., Lemenuel‐Diot, A., McIntyre, C., Brewster, M., Lum, B., & Bittner, B. (2014) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.63 · Cited by 28
Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment
Polónia, A., Leitão, D., & Schmitt, F. C. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-1903-3 · Cited by 27
Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
Li, A. C., Zhao, J., Zhao, C., Ma, Z., Hartage, R., Zhang, Y., Li, X., & Parwani, A. V. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05546-0 · Cited by 27
Chimeric DNA Vaccines: An Effective Way to Overcome Immune Tolerance
Riccardo, F., Bolli, E., Macagno, M., Arigoni, M., Cavallo, F., & Quaglino, E. (2014) · Current topics in microbiology and immunology · doi:10.1007/82_2014_426 · Cited by 28
Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index
Liu, M.-T., Huang, W., Wang, A.-Y., Huang, C.-C., Huang, C., Chang, T., Pi, C.-P., & Yang, H.-H. (2009) · Supportive Care in Cancer · doi:10.1007/s00520-009-0778-0 · Cited by 27
Fluid Biopsy for Solid Tumors: A Patient’s Companion for Lifelong Characterization of Their Disease
Nieva, J. J., & Kühn, P. (2012) · Future Oncology · doi:10.2217/fon.12.91 · Cited by 29
Use of the Monoclonal Antibody Anti-HER2 Trastuzumab in the Treatment of Metastatic Breast Cancer
Poncet, B., Bachelot, T., Colin, C., Ganne, C., Jaisson‐Hot, I., Orfeuvre, H., Péaud, P., Jacquin, J.-P., Salles, B., Tigaud, J., et al. (2008) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181637356 · Cited by 27
In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients
Vassilakopoulou, M., Togun, T. A., Dafni, U. G., Cheng, H., Bordeaux, J., Neumeister, V. M., Bobos, M., Pentheroudakis, G. E., Skarlos, D. V., Pectasides, D. G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099131 · Cited by 28
Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells
Yoshida, R., Tazawa, H., Hashimoto, Y., Yano, S., Onishi, T., Sasaki, T., Shirakawa, Y., Kishimoto, H., Uno, F., Nishizaki, M., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1249-x · Cited by 27
A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer
Heinemann, V., Gioia, D. D., Vehling‐Kaiser, U., Harich, H., Heinrich, B., Welt, A., Ziske, C. G., Deutsch, G. B., Pihusch, R., KÖLBL, H., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq409 · Cited by 27
CD147 knockdown improves the antitumor efficacy of trastuzumab in HER2-positive breast cancer cells
Xiong, L., Ding, L., Ning, H., Wu, C., Fu, K., Wang, Y., Zhang, Y., Liu, Y., & Zhou, L. (2016) · Oncotarget · doi:10.18632/oncotarget.10252 · Cited by 27
Antitumor Activity of a Monoclonal Antibody Targeting Major Histocompatibility Complex Class I–Her2 Peptide Complexes
Jain, R., Rawat, A. K., Verma, B., Markiewski, M. M., & Weidanz, J. A. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs521 · Cited by 27
Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer
Maïo, M. D., Gridelli, C., Normanno, N., Perrone, F., & Ciardiello, F. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20402 · Cited by 27
FGFR2 amplification in colorectal adenocarcinomaPreprint
Carter, J. H., Cottrell, C. E., McNulty, S. N., Vigh‐Conrad, K. A., Lamp, S., Heusel, J. W., & Duncavage, E. J. (2017) · Molecular Case Studies · doi:10.1101/mcs.a001495 · Cited by 27
Multiparametric profiling of HER2-enriched extracellular vesicles in breast cancer using Single Extracellular VEsicle Nanoscopy
Jiang, N., Saftics, A., Romano, E., Ghaeli, I., Resto, C., Robles, V. M., Das, S., Keuren‐Jensen, K. R. V., Seewaldt, V. L., & Jovanović‐Talisman, T. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02858-x · Cited by 26
Treatment-Related Biomarkers in Pulmonary Hypertension
Swaminathan, A. C., Dusek, A. C., & McMahon, T. J. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0438tr · Cited by 26
Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis
Minami, T., Kijima, T., Kohmo, S., Arase, H., Otani, Y., Nagatomo, I., Takahashi, R., Miyake, K., Higashiguchi, M., Morimura, O., et al. (2013) · Scientific Reports · doi:10.1038/srep02669 · Cited by 28
Coverage With Evidence Development and Managed Entry in the Funding of Personalized Medicine: Practical and Ethical Challenges for Oncology
Lewis, J., Kerridge, I., & Lipworth, W. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2838 · Cited by 26
HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging
Martins, C. D., Pieve, C. D., Burley, T. A., Smith, R., Ciobota, D. M., Allott, L., Harrington, K. J., Oyen, W. J. G., Smith, G. S. T., & Krämer-Marek, G. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2754 · Cited by 26
Implementation of the 2018 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2/neu Assessment by FISH in breast cancers: predicted impact in a single institutional cohort
Zare, S., Rong, J., Daehne, S., Roma, A. A., Hasteh, F., Dell’Aquila, M. L., & Fadare, O. (2019) · Modern Pathology · doi:10.1038/s41379-019-0295-8 · Cited by 26
Improved Doubly Robust Estimation in Learning Optimal Individualized Treatment Rules
Pan, Y., & Zhao, Y. (2020) · Journal of the American Statistical Association · doi:10.1080/01621459.2020.1725522 · Cited by 26
Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model
Andreata, F., Bonizzi, A., Sevieri, M., Truffi, M., Monieri, M., Sitia, L., Silva, F., Sorrentino, L., Allevi, R., Zerbi, P., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-68205-w · Cited by 26
Immuno-hyperthermia effected by antibody-conjugated nanoparticles selectively targets and eradicates individual cancer cells
Kagawa, T., Matsumi, Y., Aono, H., Ohara, T., Tazawa, H., Shigeyasu, K., Yano, S., Takeda, S., Komatsu, Y., Hoffman, R. M., et al. (2021) · Cell Cycle · doi:10.1080/15384101.2021.1915604 · Cited by 26
Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu
Tymon‐Rosario, J., Siegel, E. R., Bellone, S., Harold, J. A., Adjei, N. N., Zeybek, B., Mauricio, D., Altwerger, G. H., Menderes, G., Ratner, E., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.07.033 · Cited by 26
Critical clinical gaps in cancer precision nanomedicine development
Gan, W. W., Chan, L. W., Li, W., & Wong, T. W. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.055 · Cited by 28
Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy
Xia, W., Chen, J., Hou, W., Chen, J., Xiong, Y., Li, H., Qi, X., Xu, H. Y., Xie, Z., Li, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076843 · Cited by 27
HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
Popović, M., Silovski, T., Križić, M., & Plavetić, N. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098206 · Cited by 29
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
Liu, S., Xie, S. M., Liu, W., Gagea, M., Hanker, A. B., Nguyen, N. T., Raghavendra, A. S., Yang-Kolodji, G., Chu, F., Neelapu, S. S., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01665-w · Cited by 29
Self-citation
Solamargine induces apoptosis and enhances susceptibility to trastuzumab and epirubicin in breast cancer cells with low or high expression levels of HER2/neu
Shiu, L. Y., Liang, C. H., Li, C., Sheu, H., Tsai, E., & Kuo, K. W. (2008) · Bioscience Reports · doi:10.1042/bsr20080028 · Cited by 26
From Oncogene to Network Addiction: The New Frontier of Cancer Genomics and Therapeutics
Tonon, G. (2008) · Future Oncology · doi:10.2217/14796694.4.4.569 · Cited by 26
Changes to Adjuvant Systemic Therapy in Breast Cancer: A Decade in Review
Saurel, C. A., Patel, T. A., & Perez, E. A. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.027 · Cited by 26
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)
Goldstein, L. J., Zhao, F., Wang, Μ., Swaby, R. F., Sparano, J. A., Meropol, N. J., Bhalla, K. N., Pellegrino, C. M., Alpaugh, R. K., Falkson, C. I., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4310-9 · Cited by 26
Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer
Gregório, A. C., Lacerda, M., Figueiredo, P., Simões, S., Dias, S., & Moreira, J. N. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-017-0307-2 · Cited by 26
Herceptin Enhances the Antitumor Effect of Natural Killer Cells on Breast Cancer Cells Expressing Human Epidermal Growth Factor Receptor-2
Xiao, T., Wei, F., Wang, L., Yu, W., Zhang, N., Zhang, X., Han, Y., Yu, J., & Ren, X. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01426 · Cited by 26
Identification of HER2 Immunohistochemistry-Negative, FISH-Amplified Breast Cancers and Their Response to Anti-HER2 Neoadjuvant Chemotherapy
Gibbons‐Fideler, I., Nitta, H., Murillo, A. E., Tozbikian, G. H., Banks, P., Parwani, A. V., & Li, Z. (2018) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqy136 · Cited by 26
The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma
Ghaderi, A. A., Vasei, M., Maleck-Hosseini, S., Gharesi‐Fard, B., Khodami, M., Doroudchi, M., & Modjtahedi, H. (2002) · Pathology & Oncology Research · doi:10.1007/bf03036740 · Cited by 26
Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors
Patnaik, A., Wood, D. L., Tolcher, A. W., Hamilton, M., Kreisberg, J. I., Hammond, L. A., Schwartz, G. H., Beeram, M., Hidalgo, M. M., Mita, M. M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1886 · Cited by 26
First line chemotherapy of metastatic breast cancer
Pronzato, P., & Rondini, M. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj974 · Cited by 26
The Integration of Molecular Diagnostics With Therapeutics
Ginsburg, G. S., & Ross, J. S. (2003) · American Journal of Clinical Pathology · doi:10.1309/vmll-66y5-khq3-5kue · Cited by 26
New drugs for breast cancer
Smith, I. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09903-8 · Cited by 26
HER-2/neuOverexpression Increases the Viable Hypoxic Cell Population within Solid Tumors without Causing Changes in Tumor Vascularization
Dragowska, W. H., Warburton, C., Yapp, D. T. T., Minchinton, A. I., Hu, Y., Waterhouse, D., Gelmon, K. A., Skov, K. A., Woo, J., Masin, D., et al. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.606.2.11 · Cited by 26
Trastuzumab Use in Breast Cancer: Clinical Issues
Horton, J. (2002) · Cancer Control · doi:10.1177/107327480200900607 · Cited by 26
Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers
Waterhouse, B. R., Gijsen, M., Barber, P. R., Tullis, I. D. C., Vojnovic, B., & Kong, A. H. (2011) · Oncotarget · doi:10.18632/oncotarget.313 · Cited by 25
Anti-HER2 PLGA-PEG polymer nanoparticle containing gold nanorods and paclitaxel for laser-activated breast cancer detection and therapy
Wang, Y., Pasternak, M. M., Sathiyamoorthy, K., & Kolios, M. C. (2021) · Biomedical Optics Express · doi:10.1364/boe.419252 · Cited by 25
Tackling Current Biomedical Challenges With Frontier Biofabrication and Organ-On-A-Chip Technologies
Celikkin, N., Presutti, D., Maiullari, F., Fornetti, E., Agarwal, T., Paradiso, A., Volpi, M., Święszkowski, W., Bearzi, C., Barbetta, A., et al. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.732130 · Cited by 26
Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering
Heckel, F., Turaj, A. H., Fisher, H., Chan, H. T. C., Marshall, M. J. E., Dadas, O., Penfold, C. A., Inzhelevskaya, T., Mockridge, C. I., Alvarado, D., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03182-6 · Cited by 25
The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: A piggy-back systematic review and meta-analysis
Jackson, C., Finikarides, L., & Freeman, A. L. J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275321 · Cited by 25
Treatment of HER2-Positive Metastatic Breast Cancer Following Initial Progression
Mayer, I. A. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.s.005 · Cited by 25
Biomarker Testing for Breast, Lung, and Gastroesophageal Cancers at NCI Designated Cancer Centers
Schink, J. C., Trosman, J. R., Weldon, C. B., Siziopikou, K. P., Tsongalis, G. J., RADEMAKER, A. W., Patel, J. D., Benson, A. B., Perez, E. A., & Gradishar, W. J. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju256 · Cited by 25
Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer
Koo, D., Lee, H. J., Ahn, J. H., Yoon, D. H., Kim, S., Gong, G., Son, B. H., Ahn, S. H., & Jung, K. H. (2015) · Tumor Biology · doi:10.1007/s13277-015-3258-9 · Cited by 25
Molecular Tumor Profiling for Prediction of Response to Anticancer Therapies
Walther, Z., & Sklar, J. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318212dd6d · Cited by 25
Effect of High Copy Number of HER2 Associated With Polysomy 17 on HER2 Protein Expression in Invasive Breast Carcinoma
Shah, S., Wang, Y., Tull, J., & Zhang, S. (2009) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e31817c1af8 · Cited by 26
Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody
Wang, S., Chen, C., Meng, Y., Hu, S., Zheng, L., Song, J., Zhang, D., Li, B., & Guo, Y. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.07.007 · Cited by 25
BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells
Xing, J., Lin, L., Li, J., Liu, J., Zhou, C., Pan, H., Shu, R., Dong, B., Cao, D., Li, Q., et al. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.07.003 · Cited by 27
Academic Discovery of Anticancer Drugs: Historic and Future Perspectives
Carugo, A., & Draetta, G. F. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055645 · Cited by 25
Long-Term Preservation of Antibody-Dependent Cellular Cytotoxicity (ADCC) of Natural Killer Cells Amplified In Vitro From the Peripheral Blood of Breast Cancer Patients After Chemotherapy
Cl??menceau, B., Gallot, G., Vivien, R., Gaschet, J., Campone, M., & Vi??, H. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000175686.13368.5c · Cited by 25
Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells
Leone, F., Perissinotto, E., Cavalloni, G., Fonsato, V., Bruno, S., Surrenti, N., Hong, D., Capaldi, A., Geuna, M., Piacibello, W., et al. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0203068 · Cited by 25
Genomic Dysregulation in gastric tumors
Janjigian, Y. Y., & Kelsen, D. P. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23263 · Cited by 24
The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies
Hurvitz, S. A., & Kakkar, R. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012451205 · Cited by 24
Treatment of Metastatic Breast Cancer
Poncet, B., Colin, C., Bachelot, T., Jaisson‐Hot, I., Derain, L., Magaud, L., Fournel-Federico, C., Mousseau, M., Tigaud, J., Jacquin, J.-P., et al. (2009) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31818c08d3 · Cited by 24
Epistatic interactions and drug response
Weigelt, B., & Reis-Filho, J. S. (2013) · The Journal of Pathology · doi:10.1002/path.4265 · Cited by 26
The Use of Immunotherapy to Treat Metastatic Breast Cancer
Nicolini, A., Barak, V., Biava, P. M., Ferrari, P., Rossi, G., & Carpi, A. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180209124052 · Cited by 24
HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany
On behalf of the Nicht-interventionelle Untersuchung (NIU) HER2 Study Group, Baretton, G. B., Kreipe, H. H., Schirmacher, P., Gaiser, T., Hofheinz, R., Berghäuser, K.-H., Koch, W., Künzel, C., Morris, S., et al. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02541-9 · Cited by 24
Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer
White, J. B., Fleming, R. L., Masterson, L. A., Ruddle, B. T., Zhong, H., Fazenbaker, C. A., Strout, P., Rosenthal, K., Reed, M., Muniz-Medina, V. M., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1578611 · Cited by 24
Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma
Kamoto, S., Shinada, M., Kato, D., Yoshimoto, S., Ikeda, N., Tsuboi, M., Yoshitake, R., Eto, S., Hashimoto, Y., Takahashi, Y., et al. (2020) · Cells · doi:10.3390/cells9112529 · Cited by 24
Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer
Yang, M., Li, Kong, L., Huang, S., He, L., Liu, P., Mo, S., Lu, X., Lin, X., Xiao, Y., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164428 · Cited by 24
Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer
Zou, H., Luo, J., Guo, Y., Deng, L., Zeng, L., Pan, Y., & Li, P. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101051 · Cited by 27
Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas
Monaco, S. E., Wu, Y., Teot, L. A., & Cai, G. (2011) · Diagnostic Cytopathology · doi:10.1002/dc.21841 · Cited by 24
Cost Effectiveness of Cytotoxic and Targeted Therapy for Metastatic Breast Cancer
Blank, P. R., Dedes, K. J., & Szucs, T. D. (2010) · PharmacoEconomics · doi:10.2165/11535560-000000000-00000 · Cited by 24
Trastuzumab-induced cardiac dysfunction
Panjrath, G. S., & Jain, D. (2006) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e328025ae04 · Cited by 24
BRCC2 inhibits breast cancer cell growth and metastasis in vitro and in vivo via downregulating AKT pathway
Li, X., Kong, X., Wang, Y., & Yang, Q. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.290 · Cited by 24
Delivery of NKG2D Ligand Using an Anti-HER2 Antibody-NKG2D Ligand Fusion Protein Results in an Enhanced Innate and Adaptive Antitumor Response
Cho, H.-M., Rosenblatt, J. D., Tolba, K. A., Shin, S. J., Shin, D. S., Calfa, C., Zhang, Y., & Shin, S.-U. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1047 · Cited by 24
Microfluidics-assisted fluorescence in situ hybridization for advantageous human epidermal growth factor receptor 2 assessment in breast cancer
Nguyen, H. T., Trouillon, R., Matsuoka, S., Fiche, M., de Leval, L., Bisig, B., & Gijs, M. A. M. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2016.121 · Cited by 24
NanoString nCounter® Approach in Breast Cancer: A Comparative Analysis with Quantitative Real-Time Polymerase Chain Reaction, In Situ Hybridization, and Immunohistochemistry
Hyeon, J., Cho, S. Y., Hong, M. E., Kang, S. Y., Do, I., Im, Y. H., & Cho, E. Y. (2017) · Journal of Breast Cancer · doi:10.4048/jbc.2017.20.3.286 · Cited by 24
In Vivo Molecular Imaging Using Low-Boiling-Point Phase-Change Contrast Agents: A Proof of Concept Study
Rojas, J. D., & Dayton, P. A. (2018) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2018.08.004 · Cited by 24
Current Development of Monoclonal Antibodies in Cancer Therapy
Parakh, S., King, D., Gan, H. K., & Scott, A. M. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-23765-3_1 · Cited by 25
FISH and chips: a review of microfluidic platforms for FISH analysis
Rodriguez‐Mateos, P., Azevedo, N. F., Almeida, C., & Pamme, N. (2020) · Medical Microbiology and Immunology · doi:10.1007/s00430-019-00654-1 · Cited by 24
Which breast carcinomas need HER‐2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c‐erbB2 protein domains
Sapino, A., Coccorullo, Z., Cassoni, P., Ghisolfi, G., Gugliotta, P., Bongiovanni, M., Arisio, R., Crafa, P., & Bussolati, G. (2003) · Histopathology · doi:10.1046/j.1365-2559.2003.01708.x · Cited by 24
Nanoengineered Platform-Based Microenvironment-Triggered Immunotherapy in Cancer Treatment
Dhas, N. L., Kudarha, R. R., Kulkarni, S., Soman, S., Navti, P. D., Kulkarni, J., Roy, A. A., Colaco, V., Raychaudhuri, R., Gupta, A., et al. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2910349 · Cited by 23
The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR
Janbabai, G., Oladi, Z., Farazmandfar, T., Taghvaei, T., & Naghshvar, F. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-1965-7 · Cited by 23
Relationship between HER2 gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment
Adamczyk, A., Kruczak, A., Harazin-Lechowska, A., Ambicka, A., Grela-Wojewoda, A., Domagała-Haduch, M., Janecka-Widła, A., Majchrzyk, K., Cichocka, A., Ryś, J., et al. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s166983 · Cited by 23
Survival benefit of radiotherapy after surgery in de novo stage IV breast cancer: a population-based propensity-score matched analysis
Kim, Y., Jung, S., & Kim, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-45016-2 · Cited by 23
Prolactin hormone exerts anti-tumorigenic effects in HER-2 overexpressing breast cancer cells through regulation of stemness
Hachim, I. Y., López‐Ozuna, V. M., Hachim, M. Y., Lebrun, J. J., & Ali, S. (2019) · Stem Cell Research · doi:10.1016/j.scr.2019.101538 · Cited by 23
Invasive breast cancer: Current perspectives and emerging views
Shea, E. K. H., Koh, V. C. Y., & Tan, P. H. (2020) · Pathology International · doi:10.1111/pin.12910 · Cited by 23
Metabolomics and EMT Markers of Breast Cancer: A Crosstalk and Future Perspective
Pal, A. K., Sharma, P., Zia, A., Siwan, D., Nandave, D., Nandave, M., & Gautam, R. K. (2022) · Pathophysiology · doi:10.3390/pathophysiology29020017 · Cited by 23
Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer
Garrido, C., Manoogian, M. K., Ghambire, D., Lucas, S., Karnoub, M., Olson, M. T., Hicks, D. G., Tozbikian, G. H., Prat, A., Ueno, N. T., et al. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-023-03671-x · Cited by 23
Evaluation of immunohistochemical staining using whole‐slide imaging for HER2 scoring of breast cancer in comparison with real glass slides
Kondo, Y., Iijima, T., & Noguchi, M. (2012) · Pathology International · doi:10.1111/j.1440-1827.2012.02847.x · Cited by 23
The epidermal growth factor receptor family in breast cancer
Koutras, A. K. (2008) · OncoTargets and Therapy · doi:10.2147/ott.s3842 · Cited by 24
Effect of Trastuzumab on Health-Related Quality of Life in Patients With HER2-Positive Metastatic Breast Cancer: Data From Three Clinical Trials
Rugo, H. S., Brammer, M. G., Zhang, F., & Lalla, D. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.037 · Cited by 23
New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
Bekaii‐Saab, T., & Rose, J. S. (2011) · OncoTargets and Therapy · doi:10.2147/ott.s10188 · Cited by 23
Pertuzumab: A New Targeted Therapy for HER 2‐Positive Metastatic Breast Cancer
Malenfant, S. J., Eckmann, K. R., & Barnett, C. M. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1338 · Cited by 23
Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer
Schlüter, B., Gerhards, R., Strumberg, D., & Voigtmann, R. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0790-2 · Cited by 23
Optical Imaging with Her2-Targeted Affibody Molecules Can Monitor Hsp90 Treatment Response in a Breast Cancer Xenograft Mouse Model
van de Ven, S. M. W. Y., Elias, S. G., Chan, C. T., Miao, Z., Cheng, Z., De, A., & Gambhir, S. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3213 · Cited by 23
Targeting EGFR/HER2 heterodimerization with a novel anti-HER2 domain II/III antibody
Yu, X., Wang, L., Shen, Y., Wang, C., Zhang, Y., Meng, Y., Yang, Y., Liang, B., Zhou, B., Wang, H., et al. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.05.010 · Cited by 23
Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study
Dhir, V., Yan, A. T.-K., Nisenbaum, R. A., Sloninko, J., Connelly, K. A., Barfett, J., Haq, R., Kirpalani, A., Chan, K., Petrella, T. M., et al. (2019) · International journal of cardiac imaging · doi:10.1007/s10554-019-01648-z · Cited by 23
The Anti-Breast Cancer Effects of Green-Synthesized Zinc Oxide Nanoparticles Using Carob Extracts
Pouresmaeil, V., Haghighi, S. S., Raeisalsadati, A. S., Neamati, A., & Tabrizi, M. H. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200721132522 · Cited by 23
DNA repair and personalized breast cancer therapy
Li, S., Sjolund, A. B., Harris, L. N., & Sweasy, J. B. (2010) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20606 · Cited by 24
Self-citation

Authors: Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., Stewart, S. J., & Press, M.
Affiliations: University of Southern California (US)
ORCID: Cobleigh, Melody A.
Tripathy, Debu
Harris, Lyndsay N.
Fehrenbacher, Louis
Slamon, Dennis J.
Novotny, William F.
Shak, Steven
Press, Michael
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2002-02-01
Volume: 20
Issue: 3
Pages: 719-726
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2002.20.3.719
OpenAlex: W4239989216
Cited by: 1,860
References: 9
Citations by year: 2026: 12 · 2025: 34 · 2024: 52 · 2023: 75 · 2022: 113 · 2021: 67 · 2020: 72 · 2019: 62 · 2018: 97 · 2017: 95 · 2016: 87 · 2015: 88 · 2014: 71 · 2013: 91 · 2012: 74
FWCI: 32.63
Type: journal article
Language: en
Update notices: new_edition (2023-03-15)
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
Funders: National Cancer Institute (CA48780)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords: trastuzumab, HER2-positive breast cancer, metastatic breast cancer, first-line therapy, single-agent chemotherapy, HER2 immunohistochemistry, HER2 amplification, objective response rate, adverse cardiac events, dose-response relationship, treatment safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks